Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers?

By afschroeder • April 30, 2026

Shachar EK, Silverstein J, Kwan L, Salani R, Karlan BY, Chase DM. Are patient factors associated with real-world antibody-drug conjugate outcomes in gynecologic cancers? Gynecol Oncol. 2026 Apr 28;209:26-32. doi: 10.1016/j.ygyno.2026.04.011. Epub ahead of print. PMID: 42054783.

Tags: age, antibody drug conjugates, Ethnicity, gynecologic cancer, Hematology/Oncology, Publications, Race, Underrepresented minorities

Trial design and end points in hepatocellular carcinoma: an EASL-AASLD-ILCA consensus statement

Llovet JM, Mauro E, Rimassa L, Mazzaferro V, Pinter M, Kelley RK, Chan SL, Kulik L, Pillai A, Roberts L, Sangro B, Casanovas T, Kaplan[...]

Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome type 1

Lim A, Peluso EM, Downs IA, Horwich BH, Velez-Velez MA, Lechner MG. Severe autoimmunity after checkpoint inhibitor therapy in a patient with autoimmune polyglandular syndrome[...]

A phase 1 trial of HPV16 E7 T-cell receptor-engineered T cells in patients with relapsed/refractory HPV16-positive cancers (KITE-439 trial)

Kirtane K, Niu J, Blumenschein G, Massarelli E, Hanna GJ, Lee S, Bishop MR, Konecny GE, Mao D, Zheng Y, Rodriguez K, Kim JJ, Williams[...]